AIDS (London, England)

publication venue for

Salmonella meningitis and infection with HIV. 1990
Impact of ART intensification with CCR5 antagonist maraviroc on HIV-associated neurocognitive impairment. 2023
Brain volumetrics differ by Fiebig stage in acute HIV infection.. 37. 2023
Human galectin-9 promotes the expansion of HIV reservoirs in vivo in humanized mice.. 37. 2022
No evidence that circulating HIV-specific immune responses contribute to persistent inflammation and immune activation in persons on long-term ART.. 36. 2022
Sex differences in cytokine profiles during suppressive antiretroviral therapy.. 36. 2022
Air pollution and preclinical atherosclerotic cardiovascular disease in adolescents living with HIV: an opportunity for prevention.. 36. 2022
How informal healthcare providers improve uptake of HIV testing: qualitative results from a randomized controlled trial.. 36. 2022
Plasma galectin-9 as a predictor of adverse non-AIDS events in persons with chronic HIV during suppressive antiretroviral therapy.. 35. 2021
Candidate host epigenetic marks predictive for HIV reservoir size, responsiveness to latency reversal, and viral rebound.. 35. 2021
Impact of HIV status on systemic inflammation during pregnancy.. 35. 2021
Attributing health benefits to preventing HIV infections versus improving health outcomes among people living with HIV: an analysis in six US cities.. 35. 2021
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis.. 35. 2021
Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV.. 34. 2020
Changes in gastrointestinal microbial communities influence HIV-specific CD8+ T-cell responsiveness to immune checkpoint blockade.. 34. 2020
HIV protease inhibitor ritonavir induces renal fibrosis and dysfunction: role of platelet-derived TGF-β1 and intervention via antioxidant pathways.. 34. 2020
Elevated cardiac risk score by Atherosclerotic Cardiovascular Disease calculation is associated with albuminuria in older people living with HIV.. 34. 2020
Regional brain volumetric changes despite 2 years of treatment initiated during acute HIV infection.. 34. 2020
The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities.. 34. 2020
Plasma inflammatory biomarkers link to diffusion tensor imaging metrics in virally suppressed HIV-infected individuals.. 34. 2020
T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy.. 34. 2020
Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth.. 33. 2019
The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.. 33. 2019
Transition from paediatric to adult care among persons with perinatal HIV infection in New York City, 2006-2015.. 32. 2018
Abdominal fat depots, insulin resistance, and incident diabetes mellitus in women with and without HIV infection.. 32. 2018
Integrating cardiovascular disease risk factor screening into HIV services in Swaziland: lessons from an implementation science study.. 32 Suppl 1. 2018
Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.. 32. 2018
Frailty is strongly associated with increased risk of recurrent falls among older HIV-infected adults.. 31. 2017
Sexual network drivers of HIV and herpes simplex virus type 2 transmission.. 31. 2017
No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy.. 31. 2017
Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodies.. 30. 2016
Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy.. 30. 2016
Enhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV.. 30. 2016
Risk factors associated with acute exacerbation of chronic obstructive pulmonary disease in HIV-infected and uninfected patients.. 30. 2016
Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection.. 30. 2016
Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.. 30. 2016
Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia.. 29. 2015
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.. 29. 2015
Expanded HIV testing coverage is associated with decreases in late HIV diagnoses.. 29. 2015
Monitoring quality at scale: implementing quality assurance in a diverse, multicountry HIV program.. 29 Suppl 2. 2015
Dendritic cell type-specific HIV-1 activation in effector T cells: implications for latent HIV-1 reservoir establishment.. 29. 2015
Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries.. 28. 2014
How does population viral load vary with the evolution of a large HIV epidemic in sub-Saharan Africa?. 28. 2014
The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.. 28. 2014
Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density.. 27. 2013
Efficacy of a culturally congruent HIV risk-reduction intervention for behaviorally bisexual black men: results of a randomized trial.. 27. 2013
Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?. 27. 2013
Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania.. 27. 2013
Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women.. 27. 2013
Vitamin D insufficiency may impair CD4 recovery among Women's Interagency HIV Study participants with advanced disease on HAART.. 27. 2013
Only a fraction of new HIV infections occur within identifiable stable discordant couples in sub-Saharan Africa.. 27. 2013
Fractures after antiretroviral initiation.. 26. 2012
The HIV care continuum: no partial credit given.. 26. 2012
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.. 26. 2012
HIV as an independent risk factor for incident lung cancer.. 26. 2012
Small for gestational age birth outcomes in pregnant women with perinatally acquired HIV.. 26. 2012
Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis.. 26. 2012
Testosterone replacement therapy and polycythemia in HIV-infected patients.. 26. 2012
Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.. 26. 2012
Renal dysfunction among HIV-infected patients starting antiretroviral therapy.. 25. 2011
Seroincidence of 2009 H1N1 infection in HIV-infected and HIV-uninfected women prior to vaccine availability.. 25. 2011
Peripheral neuropathy in HIV: prevalence and risk factors.. 25. 2011
HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study.. 24. 2010
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.. 24. 2010
HIV/AIDS among female sex workers, injecting drug users and men who have sex with men in Lebanon: results of the first biobehavioral surveys.. 24 Suppl 2. 2010
The impact of CCL3L1 copy number in an HIV-1-infected white population.. 24. 2010
Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients.. 23. 2009
Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment.. 23. 2009
Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression.. 23. 2009
Persistent HIV RNA shedding in semen despite effective antiretroviral therapy.. 23. 2009
Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women's interagency HIV study.. 23. 2009
HIV infection and the risk of diabetes mellitus.. 23. 2009
Sustained release of microbicides by newly engineered vaginal rings.. 23. 2009
The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.. 22. 2008
Incidence and risk factors for verrucae in women.. 22. 2008
No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa.. 22. 2008
Suppression of HIV-1 plasma viral load below detection preserves IL-17 producing T cells in HIV-1 infection.. 22. 2008
Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy.. 21 Suppl 6. 2007
Chronic kidney disease in HIV infection: an urban epidemic.. 21. 2007
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.. 21. 2007
Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.. 21. 2007
Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation.. 20. 2006
Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations.. 20. 2006
Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation.. 20. 2006
Multidrug-resistant tuberculosis at an HIV testing center in Haiti.. 20. 2006
Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients.. 19. 2005
Effects of hepatic function and hepatitis C virus on the nervous system assessment of advanced-stage HIV-infected individuals.. 19 Suppl 3. 2005
The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects.. 19 Suppl 3. 2005
Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations.. 19. 2005
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.. 18. 2004
The cost-effectiveness of elective Cesarean delivery to prevent hepatitis C transmission in HIV-coinfected women.. 18. 2004
The prevalence of antiretroviral drug resistance in the United States.. 18. 2004
Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia.. 18. 2004
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.. 18. 2004
Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine.. 17. 2003
Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions.. 16. 2002
Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: Recommendations of the UNAIDS Reference Group on Estimates, Modelling and Projections.. 16. 2002
Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels.. 16. 2002
Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells.. 16. 2002
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.. 15. 2001
Integration of tuberculosis screening at an HIV voluntary counselling and testing centre in Haiti.. 15. 2001
The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.. 15. 2001
A simple and rapid magnetic bead separation technique for the isolation of tetramer-positive virus-specific CD8 T cells.. 15. 2001
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.. 15. 2001
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.. 14. 2000
HIV infection in Haiti: natural history and disease progression.. 14. 2000
Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry.. 14. 2000
Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection.. 14. 2000
Quantification of HIV-1-specific T-cell responses at the mucosal cervicovaginal surface.. 14. 2000
A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).. 14. 2000
Energy balance, viral burden, insulin-like growth factor-1, interleukin-6 and growth impairment in children infected with human immunodeficiency virus.. 14. 2000
Global distribution of the CCR2-64I/CCR5-59653T HIV-1 disease-protective haplotype.. 14. 2000
Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team.. 13. 1999
A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals.. 13. 1999
The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection.. 13. 1999
Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function.. 12. 1998
Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry.. 10. 1996
Physical disability in a cohort of persons with AIDS: data from the AIDS Time-Oriented Health Outcome Study.. 10. 1996
Genetic heterogeneity of the V3 region of the HIV-1 envelope glycoprotein in Brazil. Brazilian Collaborative AIDS Research Group.. 7. 1993
Heterosexual transmission of HIV in a cohort of couples in New York City.. 7. 1993
Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals.. 7. 1993
The spectrum of clinical and pathological manifestations of AIDS in a consecutive series of autopsied patients in Mexico.. 6. 1992
The prevalence of invasive amebiasis is not increased in patients with AIDS.. 6. 1992
An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope.. 4. 1990
Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS.. 4. 1990
Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.. 4. 1990
Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4.. 4. 1990
Antibodies to a putative HIV gp41 immunosuppressive peptide, pHIVIS (583-599), do not correlate significantly with outcome in HIV infection.. 4. 1990
Psychological responses to serological testing for HIV.. 4. 1990
A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy: virologic observations. Ribavirin-LAS Collaborative Group.. 4. 1990
An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1.. 3. 1989
An aberrant subclass pattern of HIV-specific immunoglobulin G in sera from haemophiliacs.. 2. 1988
Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS.. 2. 1988
Development of AIDS, HIV seroconversion, and potential co-factors for T4 cell loss in a cohort of intravenous drug users.. 1. 1987
Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City.. 1. 1987
HIV/AIDS in the Middle East and North Africa: new study methods, results, and implications for prevention and care.. 24 Suppl 2. 2010
Distinct inflammatory profiles linked to cardiovascular disease risk in HIV infection: implications for the design of preventive and therapeutic interventions. 2023
Can the 'Ending the HIV Epidemic' initiative transition the USA towards HIV/AIDS epidemic control? 2020
Renal dysfunction and schistosomiasis among HIV-infected patients starting antiretroviral therapy in Mwanza, Tanzania. 2015
Increased transmigration of intermediate monocytes associated with atherosclerotic burden in people with HIV on antiretroviral therapy. 2023
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria. 2021
Authors' reply, Xia et al. 2019
Atazanavir use and carotid intima media thickness progression in HIV: potential influence of bilirubin. 2016
Biomarkers for sexual behaviour change: a role for nonpaternity studies? 2014
Understanding HIV epidemics: aggregate viral load metrics and 'smoking guns'. 2013
Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load? 2013
Pyogenic brain abscess in toxoplasmosis lesion in a patient with AIDS. 2010
Successful initiation of an anal cancer screening and treatment program at a New York City HIV clinic. 2010
Prolonged viral suppression without therapy in an HIV-1 seroconverter following early antiretroviral therapy and daily interleukin-2. 2010
Why don't physicians test for HIV? 2008
Successful treatment of marginal zone lymphoma with splenectomy alone despite HIV infection. 2007
Efavirenz: innocent bystander or direct nephrotoxin? 2007
Fatal hepatorenal failure and thrombocytopenia with SU5416, a vascular endothelial growth factor Flk-1 receptor inhibitor, in AIDS-Kaposi's sarcoma. 2007
Remission of AIDS-associated progressive multifocal leukoencephalopathy with combined cidofovir and radiotherapy: a case report. 2006
Acute respiratory manifestations of the abacavir hypersensitivity reaction. 2006
Spinal epidural lipomatosis: a manifestation of HAART-associated lipodystrophy. 2005
Progressive outer retinal necrosis in a 73-year-old man: treatment with valganciclovir. 2003
Hepatitis C in an urban population infected with the human immunodeficiency virus. 1999
Re-evaluation of time to progression of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients clinically resistant to ganciclovir. 1997
Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. 1997
Antigenicity of the HIV-2 V3 loop. 1992
Refusal of zidovudine by HIV-positive patients. 1992
Interrater reliability of the Karnofsky Performance Status in an HIV-infected sample. 1991
Immunological incompetence in AIDS. 1991
Inclusion of women in HIV research and clinical trials.. 37. 2023
Disclosure of their HIV status to perinatally infected youth using the adapted Blasini disclosure model in Haiti and the Dominican Republic: preliminary results.. 29 Suppl 1. 2015
Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines.. 24. 2010
HIV and tuberculosis in Russia and eastern Europe: sounding the alarm.. 23. 2009
Antiretroviral therapies for treatment-experienced patients: current status and research challenges.. 19. 2005
Osteonecrosis in HIV disease: epidemiology, etiologies, and clinical management.. 17. 2003
Kinetics of the HIV-CD4 interactions and virus-cell fusion.. 6. 1992
Cytotoxic T-cell recognition of HIV proteins and peptides.. 5. 1991
Global population-level association between herpes simplex virus 2 prevalence and HIV prevalence. 2018
Transforming growth factor-β1-mediated cardiac fibrosis: potential role in HIV and HIV/antiretroviral therapy-linked cardiovascular disease. 2016
Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa. 2015
Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment. 2013
Novel clinical trial designs for the development of new antiretroviral agents. 2012
Epidemiology of HIV infection in the Middle East and North Africa. 2010
HIV clinical trial design for antiretroviral development: moving forward. 2008
Why don't physicians test for HIV? A review of the US literature. 2007
Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. 2007
Mood and substance use disorders in older adults with HIV/AIDS: methodological issues and preliminary evidence. 2004
New observations on CD8 cell responses. 2003
New drugs for HIV therapy. 2002
Low-dose daily interleukin-2 immunotherapy: accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity. 2001
The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. 1999
Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents. 1998
HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. 1995
HIV-1 neutralization directed to epitopes other than linear V3 determinants. 1991
The role of the V3 loop of gp120 in HIV infection. 1991
AIDS 1989. Vaccines and immunology: overview. 1989
T-cell strategies in AIDS vaccines: MHC-restricted T-cell responses to HIV proteins. 1989
Treatment of gastrointestinal infections. 1988
Vaccines and immunology. Overview. 1988

VIVO Weill Cornell Medical College

AIDS (London, England) Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)